Open AccessOutcomes of iontophoretic corneal collagen crosslinking in keratoconic eyes with very thin corneas
Author(s) -
Alina Cantemir,
Anisia-Iuliana Alexa,
Bogdan Gabriel Galan,
Nicoleta Anton,
Roxana Elena Ciuntu,
Ciprian Danielescu,
D Chiseliţă,
D Costin
Publication year - 2017
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000008758
Subject(s) - keratoconus , medicine , keratometer , ophthalmology , corneal pachymetry , corneal collagen cross linking , ultraviolet a , intraocular pressure , visual acuity , cornea , dermatology
The purpose of this retrospective study was to report the results of iontophoretic corneal collagen crosslinking (I-CXL) with riboflavin and ultraviolet A irradiation in patients affected by keratoconus, each with thinnest pachymetry values of <400 μ (with epithelium) and not treatable using standard epithelium-off technique. Fifteen eyes of 15 patients affected by progressive keratoconus and with thinnest pachymetry values <400 μ underwent I-CXL. The uncorrected (UDVA) and corrected (CDVA) distance visual acuity, maximum and minimum keratometry (K max and K min) readings, corneal thickness at the thinnest point (CTTP), endothelial cell density (ECD), and intraocular pressure (IOP) were assessed before I-CXL, at 1, 3, 6, and 12 months postoperatively. The mean UDVA and CDVA significantly increased 12 months after I-CXL ( P = .002 for both comparisons). The K max readings significantly decreased at 6 and 12 months postoperatively ( P = .04 and P = .02, respectively). The mean CTTP improved at the end of the follow-up ( P = .008). ECD was unchanged. No side effects or damage to the limbal region was observed during the follow-up period. I-CXL has been proved to be effective in halting keratoconus progression in eyes with very thin corneas, with no side effects during the follow-up period. This procedure could be used in patients with more advanced keratoconus.